RECRUITING

Aspirin and Preeclampsia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.

Official Title

Aspirin to Prevent Cardiac Dysfunction in Preeclampsia

Quick Facts

Study Start:2021-02-15
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04479072

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Pregnant Adults between 18 and 45 years of age
  2. 2. Diagnosed with preeclampsia
  3. 3. Presenting for delivery with a singleton gestation.
  1. 1. We will exclude patients in labor
  2. 2. Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation
  3. 3. Plan to deliver outside of the participating site
  4. 4. Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.
  5. 5. Aspirin allergy
  6. 6. Clear indication for aspirin therapy or contraindication to aspirin therapy
  7. 7. Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)
  8. 8. Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study.
  9. 9. Those who cannot provide consent

Contacts and Locations

Study Contact

Sajid Shahul, MD, PhD
CONTACT
773-398-2956
sshahul1@dacc.uchicago.edu
Colleen Duncan, RN
CONTACT
7738342892
cduncan@bsd.uchicago.edu

Study Locations (Sites)

University of Chicago Hospital
Chicago, Illinois, 60637
United States

Collaborators and Investigators

Sponsor: University of Chicago

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-02-15
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2021-02-15
Study Completion Date2025-12-31

Terms related to this study

Keywords Provided by Researchers

  • Preeclampsia
  • Postpartum GLS Levels
  • Postpartum Activin A Levels
  • Aspirin
  • Cardiac Postpartum Therapy
  • Hypertension
  • Cardiovascular disease

Additional Relevant MeSH Terms

  • Preeclampsia Postpartum